Physician profile
Andre Halabu
NPI 1902487119
$3,139.49
in general payments reported to CMS, 2019-2025
26 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $776 · 2024: $886 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,099.05 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $566.71 | 2023-2025 | Airsupra, Fasenra, Farxiga |
| Novo Nordisk INC | $525.80 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $258.60 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.18 | 2024-2025 | Jardiance, Synjardy |
| Arcutis Biotherapeutics, INC. | $220.64 | 2023-2024 | Zoryve |
| Abbvie INC. | $170.41 | 2023-2025 | |
| Astellas Pharma US INC | $156.75 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $147.97 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $126.00 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $114.00 | 2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $99.99 | 2024-2025 | |
| Glaxosmithkline, LLC. | $93.19 | 2025 | Shingrix, Trelegy Ellipta |
| Intuitive Surgical, INC. | $92.07 | 2025 | |
| Lilly USA, LLC | $70.37 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $45.48 | 2024-2025 | Otezla, Repatha, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $41.68 | 2025 | |
| Idorsia Pharmaceuticals US INC | $19.80 | 2024 | Quviviq |
| Dexcom, INC. | $19.41 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $18.21 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.08 | 2023 | Eliquis |
| Corcept Therapeutics | $18.08 | 2024 | Korlym |
| Currax Pharmaceuticals LLC | $16.54 | 2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.32 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $14.73 | 2023 | Vaxneuvance, Gardasil 9 |
| Evoke Pharma, INC. | $13.84 | 2025 | |
| Esperion Therapeutics, INC. | $13.64 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Halabu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.